Letaplimab represents a unique therapeutic approach for addressing complement-mediated conditions. This monoclonal antibody targets the C1q protein, a critical molecule of the complement system, potentially disrupt https://zoyahino956691.blog5.net/92092101/letaplimab-a-groundbreaking-therapeutic-approach